These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 26643016)

  • 1. Efficacy of PD-1 blockade in tumors with MMR deficiency.
    Lee V; Le DT
    Immunotherapy; 2016; 8(1):1-3. PubMed ID: 26643016
    [No Abstract]   [Full Text] [Related]  

  • 2. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy.
    Zhao P; Li L; Jiang X; Li Q
    J Hematol Oncol; 2019 May; 12(1):54. PubMed ID: 31151482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade.
    Lee V; Murphy A; Le DT; Diaz LA
    Oncologist; 2016 Oct; 21(10):1200-1211. PubMed ID: 27412392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?
    Nebot-Bral L; Coutzac C; Kannouche PL; Chaput N
    Bull Cancer; 2019 Feb; 106(2):105-113. PubMed ID: 30342749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MMR deficiency may lead to a high immunogenicity and then an improvement in anti-PD-1 efficacy for metastatic colorectal cancer.
    Aguiar PN; Tadokoro H; Forones NM; de Mello RA
    Immunotherapy; 2015; 7(11):1133-4. PubMed ID: 26568256
    [No Abstract]   [Full Text] [Related]  

  • 6. Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response.
    Mandal R; Samstein RM; Lee KW; Havel JJ; Wang H; Krishna C; Sabio EY; Makarov V; Kuo F; Blecua P; Ramaswamy AT; Durham JN; Bartlett B; Ma X; Srivastava R; Middha S; Zehir A; Hechtman JF; Morris LG; Weinhold N; Riaz N; Le DT; Diaz LA; Chan TA
    Science; 2019 May; 364(6439):485-491. PubMed ID: 31048490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmed death 1 blockade, an Achilles heel for MMR-deficient tumors?
    Lin AY; Lin E
    J Hematol Oncol; 2015 Nov; 8():124. PubMed ID: 26542241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.
    Bouffet E; Larouche V; Campbell BB; Merico D; de Borja R; Aronson M; Durno C; Krueger J; Cabric V; Ramaswamy V; Zhukova N; Mason G; Farah R; Afzal S; Yalon M; Rechavi G; Magimairajan V; Walsh MF; Constantini S; Dvir R; Elhasid R; Reddy A; Osborn M; Sullivan M; Hansford J; Dodgshun A; Klauber-Demore N; Peterson L; Patel S; Lindhorst S; Atkinson J; Cohen Z; Laframboise R; Dirks P; Taylor M; Malkin D; Albrecht S; Dudley RW; Jabado N; Hawkins CE; Shlien A; Tabori U
    J Clin Oncol; 2016 Jul; 34(19):2206-11. PubMed ID: 27001570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
    Le DT; Durham JN; Smith KN; Wang H; Bartlett BR; Aulakh LK; Lu S; Kemberling H; Wilt C; Luber BS; Wong F; Azad NS; Rucki AA; Laheru D; Donehower R; Zaheer A; Fisher GA; Crocenzi TS; Lee JJ; Greten TF; Duffy AG; Ciombor KK; Eyring AD; Lam BH; Joe A; Kang SP; Holdhoff M; Danilova L; Cope L; Meyer C; Zhou S; Goldberg RM; Armstrong DK; Bever KM; Fader AN; Taube J; Housseau F; Spetzler D; Xiao N; Pardoll DM; Papadopoulos N; Kinzler KW; Eshleman JR; Vogelstein B; Anders RA; Diaz LA
    Science; 2017 Jul; 357(6349):409-413. PubMed ID: 28596308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mismatch Repair-Deficient Cancers Are Targets for Anti-PD-1 Therapy.
    Kelderman S; Schumacher TN; Kvistborg P
    Cancer Cell; 2015 Jul; 28(1):11-3. PubMed ID: 26175412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer.
    Bartoletti M; Giorda G; Viel A; Fornasarig M; Zdjelar A; Segatto E; Sorio R; Corsetti S; Scalone S; Nicoloso MS; Pivetta T; Lucia E; Clemente N; Palazzari E; Canzonieri V; Puglisi F
    Curr Oncol; 2022 Jul; 29(8):5209-5212. PubMed ID: 35892982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New checkpoint inhibitors ride the immunotherapy tsunami.
    Mullard A
    Nat Rev Drug Discov; 2013 Jul; 12(7):489-92. PubMed ID: 23812256
    [No Abstract]   [Full Text] [Related]  

  • 13. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy.
    Swaika A; Hammond WA; Joseph RW
    Mol Immunol; 2015 Oct; 67(2 Pt A):4-17. PubMed ID: 25749122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering Tumor Hypersusceptibility to Checkpoint Immunotherapy.
    Fernández A
    Trends Cancer; 2017 Oct; 3(10):675-677. PubMed ID: 28958385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies.
    Graham LS; Montgomery B; Cheng HH; Yu EY; Nelson PS; Pritchard C; Erickson S; Alva A; Schweizer MT
    PLoS One; 2020; 15(5):e0233260. PubMed ID: 32453797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinically applicable cases of anti-programmed cell death protein 1 immunotherapy for colorectal cancer patients.
    Chikatani K; Chika N; Suzuki O; Sakimoto T; Ishibashi K; Eguchi H; Okazaki Y; Ishida H
    Surg Today; 2020 Dec; 50(12):1694-1698. PubMed ID: 32253514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system.
    Pico de Coaña Y; Choudhury A; Kiessling R
    Trends Mol Med; 2015 Aug; 21(8):482-91. PubMed ID: 26091825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Genetic Mutation Accumulation and Clinical Outcome of Immune Checkpoint Blockade Therapy].
    Takahashi M
    Gan To Kagaku Ryoho; 2016 Jun; 43(6):678-82. PubMed ID: 27306805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microsatellite instability and mismatch repair deficiency in the era of precision immuno-oncology.
    Mann SA; Cheng L
    Expert Rev Anticancer Ther; 2020 Jan; 20(1):1-4. PubMed ID: 31842633
    [No Abstract]   [Full Text] [Related]  

  • 20. Releasing the Brakes on Cancer Immunotherapy.
    Ribas A
    N Engl J Med; 2015 Oct; 373(16):1490-2. PubMed ID: 26348216
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.